BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsEarnings

Earnings Driven by Treasury and Treasury-Related Asset Appreciation

Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; "Enlivex" or "the Company") today reported financial results and business highlights for the year ended December 31, 2025.

Net income for the year ended...

Related news

ENLVEnlivex Therapeutics2026-07-20 13:00 EST

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

ENLVEnlivex Therapeutics2026-06-22 13:45 EST

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

CUECue Biopharma Inc2026-08-14 20:05 EST

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CADLCandel Therapeutics2026-08-13 12:05 EST

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

SLSSELLAS Life Sciences Group, Inc.2026-08-11 20:05 EST

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

NXTCNextCure2026-08-06 20:01 EST

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

BMYBMYBristol-Myers Squibb Company2026-07-30 10:59 EST

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States